Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Wrangles With Generic Exclusivity, Looks To Courts For Direction

Executive Summary

For FDA, resolving 180-day exclusivity issues may be as difficult as Lisbeth Salander’s quest to figure out Fermat’s Last Theorem.

You may also be interested in...



US FDA Gives Directions On Navigating Generic 180-Day Exclusivity Maze

Draft guidance sums up agency’s policies for determining exclusivity, clarifies when the clock starts for failure to market.

US FDA Gives Directions On Navigating Generic 180-Day Exclusivity Maze

Draft guidance sums up agency’s policies for determining exclusivity, clarifies when the clock starts for failure to market.

FDA Sets New Goal For Biosimilar, Drug Promotion Guidances

Agency plans to issue 102 new and revised draft guidances this year, including those on use of multiple endpoints in clinical trials, 180-day exclusivity, and ANDA refuse-to-receive standards.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel